Use of laser interferometry for measuring concrete substrate roughness in patch repairs

The overall success and long-term durability of a patch repair is significantly influenced by the bond developed at the interface between the concrete substrate and the repair material. In turn, the bond strength is influenced by the topography (roughness) of the substrate surface after removal of the defective concrete. However, different removal methods of defective concrete produce substrate surfaces with different topographies. Hence, the ability to measure and characterise the topography of substrate surfaces is of great importance for evaluating the effectiveness of different removal methods. In this paper, the effect of two removal methods: electric chipping hammers and Remote Robotic Hydro-erosion (RRH) on the surface roughness is investigated through the use of a prototype non-contact (optical) laser interferometry measuring device. Laboratory results show that the above equipment can be used to characterise substrate roughness and confirm the ability of RRH to create rougher surfaces as opposed to chipping hammers

Factors affecting the accuracy of areal surface texture data extraction from X-ray CT

The ability to perform non-destructive areal surface analysis of the internal surfaces of additively manufactured (AM) components would be advantageous during product development, process control and product acceptance. Currently industrial X-ray computed tomography (XCT) is the only practical method for imaging the internal surfaces of AM components. A viable method of extracting useable areal surface texture data from XCT scans has now been developed and this paper reports on three measurement and data processing factors affecting the value of areal parameters per ISO 25178-2 generated from XCT volume data using this novel technique

Вплив занять з фізичної підготовки на військово-патріотичне виховання здобувачів вищої освіти

Любчич Р. І. Вплив занять з фізичної підготовки на військово-патріотичне виховання здобувачів вищої освіти / Р. І. Любчич, Т. Г. Шевченко, Є. І. Хоролець // Актуальні проблеми розвитку службово-прикладних, традиційних та східних єдиноборств: зб. наук. пр. «ΛΌГOΣ» за матеріалами XIV міжнар. наук.-метод. конф. (м. Харків, 20 листоп. 2020 р.) / [ Швець Д. В. (Гол. оргком.)], Європейська наукова платформа, Харків. нац. ун-т внутр. справ. - Харків, 2020. - С. 28-29.Зазначено, що заняття з фізичного виховання (спеціальної фізичної підготовки) тісно пов’язані із вихованням загальної культури майбутніх офіцерів-правоохоронців, розвитком їх духовної сфери та іншими соціальними процесами. Головна цінність занять полягає у прояві: духовності, гуманності, формування культури спілкування. Головна ціль фізичної підготовки – підготовка всебічно розвиненої особистості, готової до виконання завдань за призначенням. Отмечено, что занятия по физическому воспитанию (специальной физической подготовке) тесно связаны с воспитанием общей культуры будущих офицеров-правохранителей, развитием их духовной сферы и другими социальными процессами. Главная ценность занятий состоит в проявлении: духовности, гуманности, формировании культуры общения. Главная цель физической подготовки – подготовка всесторонне развитой личности, готовой к выполнению задач по назначению. It is noted that physical education classes (special physical training) are closely related to the education of the general culture of future law enforcement officers, the development of their spiritual sphere and other social processes. The main value of the classes is the manifestation of: spirituality, humanity, the formation of a culture of communication. The main goal of physical training is the preparation of a comprehensively developed personality, ready to perform tasks as intended

Roughness

status: Published onlin

Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle-5

Sence of chimeric GvpC proteins. Electroblotted wild type gas vesicles samples (wt-GV) prepared from the NRC-1 were incubated with purified rabbit anti-GvpC antibody or with monkey anti-SHIV antibody. As shown, the GvpC protein is clearly detected by anti-GvpC antibody (), but this protein is not detected by anti-SHIV antibody (). In cell lysates, Tat and Rev sequences contained in the putative recombinant GvpC protein are each detected using anti-SHIV antibody (plasma number R94085) from a monkey infected with SHIV virus (). The recombinant chimeric protein bands identified here correspond in size to bands identified with anti-GvpC antibody (see ).<p><b>Copyright information:</b></p><p>Taken from "Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle"</p><p>http://www.biomedcentral.com/1472-6750/8/9</p><p>BMC Biotechnology 2008;8():9-9.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2270826.</p><p></p

erythrospermum

Taraxacum erythrospermum Andrzejowskired-seed dandelionTaraxacum laevigatumSource of first western tributary of Red Rock Canyon on southeast spur of Mt. Glendowanwet, springy area5800 fee

Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle-8

Ments of sera taken at week 43 demonstrate that notable titers remain at this very late time point: 1:160 for Rev; and for Tat and Nef1, the titers are ≥ 1:1,280. : for this graph the absorbance scale is 0.0 – 5.0 and note also that indicates only one animal remained in the Rev group at 43 weeks.<p><b>Copyright information:</b></p><p>Taken from "Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle"</p><p>http://www.biomedcentral.com/1472-6750/8/9</p><p>BMC Biotechnology 2008;8():9-9.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2270826.</p><p></p

Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle-0

Thin the gene, allowed insertion of the exogenous DNA fragments. The unique restriction enzyme sites Spe I, AsiS I and Afl II allowed manipulation/isolation of this cluster of gas vesicle genes by appropriate restriction digests. The antibiotic resistance genes are indicated with the boxes and allow selection of transformed or SD109 using Ampicilin (Amp) and Mevinolin (mev), respectively.<p><b>Copyright information:</b></p><p>Taken from "Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle"</p><p>http://www.biomedcentral.com/1472-6750/8/9</p><p>BMC Biotechnology 2008;8():9-9.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2270826.</p><p></p

Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle-10

He recombinant genes. The agarose gel shows the PCR amplicon sizes of the selected SIV gene fragments and are indicated along the horizontal axis: :150, 243 and :642 bp. Their presence inherently verifies SIV DNA retention by each r-genes. The Control (C) is an internal fragment from the gene and serves as a marker for the migration of this 350 bp fragment. The relevant primers are shown in Table 1.<p><b>Copyright information:</b></p><p>Taken from "Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle"</p><p>http://www.biomedcentral.com/1472-6750/8/9</p><p>BMC Biotechnology 2008;8():9-9.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2270826.</p><p></p

Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle-2

or carrying the native leftward operon of the gas vesicle gene cluster and the rightward operon carrying an inserted SIV fragment of interest. Original magnifications 1,000 ×.<p><b>Copyright information:</b></p><p>Taken from "Recombinant gas vesicles from . displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle"</p><p>http://www.biomedcentral.com/1472-6750/8/9</p><p>BMC Biotechnology 2008;8():9-9.</p><p>Published online 31 Jan 2008</p><p>PMCID:PMC2270826.</p><p></p